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THE ANTIPERSPIRANT ACTION OF TOPICALLY
APPLIED ANTICHOLINERGICS * t
F. S. KILMER MACMILLAN, Pn.D., HERBERT H. RELLER, PH.D.
AND FRED H. SYNDER, Pn.D.
The ecerine sweat glands are innervated by
cholinergie postganglionie fibers of the sympa-
thetic system. This anomalous situation has
been amply established and both systemic and
locally administered sympatholyties, or anti-
eholinergies, have been shown to inhibit ecerine
sweating. There has long been the desire to
inhibit locally hyperhidrosis with topically ap-
plied anticholinergies without notable success to
the present time.
Iontophoretie introduction of 1% scopolamine
and four other anticholinergie compounds into
the skin has been shown by Shelley and Horvath
(1) to inhibit locally eecrine sweating. In order
of effectiveness after scopolamine hydrobro-
mide were atropine methyl nitrate, atropine
sulfate, homatropine methyl bromide, and
scopolamine N-oxide hydrobromide. Six syn-
thetic compounds were ineffective. The inhibi-
tion due to scopolamine lasted about 10 days.
Topical applications (without iontophoresis) of
1% and 18% scopolamine hydrobromide were
also shown to cause sweat inhibition locally
lasting 5—6 days and about 30 days, respectively.
Concern was expressed, however, over the pos-
sible systemic effects which might be expected
if superabsorption would occur, for example,
through diseased or damaged skin.
Synthetic drugs were also studied by Brun
and Hnnziker (2) and Vultee (3) with and
without iontophoresis. Limited effectiveness was
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found unless iontophoresis was used. Brun
ranked the materials he tested in the following
order of decreasing effectiveness: atropine,
scopolamine, Antrenyl, Probanthine, Banthine,
Prantal, Bnseopan, and homatropine. He con-
cluded that a practical and safe topical anti-
eholinergie was not available. Stoughton (4)
has recently reported on the effectiveness of a
synthetic compound with simple topical appli-
cation finding moderately good effectiveness.
This report deals with studies which were
begun some years ago in which a large number of
the then cormnereially available drugs were
evaluated. Following this evaluation a much
larger number of research compounds from
several pharmaceutical companies and univer-
sity laboratories were tested for their ability
to inhibit locally sweating by topical application.
This work led to the synthesis of a number of
highly effective compounds which possess a
wide margin of safety for topical use as sweat
gland inhibitors.
METHODS AND MATERIALS
Test for Primory Irritation of the Skin and Sys-
temic Side Effects
All anticholinergic compounds evaluated were
screencd for potential irritation and systemic side
effects on rabbit skin before testing on humans.
1.0 ml of a 1.0% aqueous solution of the anti-
cholinergic was applied topically to an area of
4 x 3 incbes of the back of albino rabbits that had
been clipped 24 hours prior to application. Each
rabbit was checked for erythema and mydriasis 1.
5, and 24 hours following application.
Forearm Antiperspirant Test
In order to test anticholinergic compounds and
antiperspirant formulations in which minor changes
of concentrations of active and inert ingredients
are made, a forearm testing procedure has been de-
vised. Circles, 4.5 cm' in area, are marked on the
inner aspect of the forearm about ¾ inch apart.
The antiperspirant solution is applied with a cot-
ton-tipped swab and allowed to dry. This is done
three times for each area. A total of 0.1—02 ml is
applied in this manner.
After an appropriate time interval, often about
5 hours, the forearm is washed with soap and water
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and rinsed thoroughly to remove any excess of the
material. The degree of sweat inhibition is then
visualized using the starch-iodine technic described
by Wada (5). The visualization procedure is usu-
ally repeated, without further treatment with the
antiperspirant agent, at 24 and 48 hours. The grad-
ing system is as follows:
0 = no sweat inhibition; control and treated
areas are identical.
1 = poor sweat inhibition; treated area just
definitely discernible because of fewer
droplets.2 = fair inhibition; treated area has only about
half of its glands functioning.
3 = good inhibition; only a few scattered drop-
lets present in the treated area.
4 excellent inhibition; no sweat droplets pres-
ent in the treated area. Control may extend
beyond the area of treatment. A "+" is
added to the grade to indicate this.
Axillary Antiperspirant Test
0.5 to 1.0 ml of the antiperspirant solution (av.
quantity applied) is applied to the whole axillary
surface by means of a cotton-tipped swab or from
a commercial roll-on dispenser. After a suitable
time interval, the subject is placed in a 100 F room
which has a relative humidity of about 40—50%,
and gravimetric sweat collections are made. Sweat
collectioas are made with tared pads (Webril)
which are 2½ x 5 inches in sixe. These are placed
snugly in the axillary vault and allowed to remain
for 10 minutes. The pads are then placed in tared,
tightly covered jars and weighed to determine the
weight of sweat that was produced. Control sweat
collections are taken for each individual subject,
usually over a 3-week period, in order to establish
the normal sweating pattern under the above de-
scribed conditions. As many successive 10-minute
collections can be made as required. Usually, at
TABLE I
Commercial compounds
least 8 separate collections are taken and as many
as 20 or more may be taken over an 8-hour day.
Intracutaneous Injection Studies
Intracutaneous injection of several tertiary and
quaternary anticholinergics was carried out in par-
allel with their topical application to the skin.1
Sweat inhibition was visualized by the starch-iodine
technic. This affords a means of approximating the
extent of percutaneous penetration.
0.05 ml of the anticholinergic solution was in-
jected in saline at concentrations ranging from 10
to 10_s. 0.001 to 1.0% solutions of the anticholiner-
gics were used for topical applications.
Preparation of Tertiary and Quaternary Salts of
Scopolamine and Atropine Esters
The tertiary salts of scopolamine and atropine
esters were prepared by reacting 0.1 mole of an-
hydrous scopolamine hydrobromide or anhydrous
atropine hydrobromide with 0.15 mole of the ap-
propiate alkyl or aryl acid chloride in the presence
of anhydrous pyridine (6). The ester is then iso-
lated, in most cases, as a crystalline acid salt usu-
ally in the form of the hydrobromide in good yield
(80 to 90% over-all yield).
Quaternary salts of esters of scopolamine and
atropine were prepared by adding a considerable
excess of the requisite alkyl halide, usually methyl
bromide, to a solution of scopolamine ester or at-
ropine ester free base in benzene or methyl ethyl
ketone. An excellent yield was obtained by allow-
ing the solution to stand at room temperature for
2 to 3 days.
RESULTS
I. Commercial and Research Compounds
1 This work was done under the supervision of
Dr. Richard B. Stoughton, Department of Derma-
tology, Western Reserve University Medical
School.
Active
Scopolamine Methyl Br
Aminopentamide
Dibutoline Sulfate
Slightly Active
Scopolamine HBr
ilomatropine Methyl
Br
Antrenyl
Nacton
Pipenzolate Methyl Br
Mephenesin
Piperidolate
Scopolamine Butyl Br
Table I lists the results obtained with 25
commercially available compounds. The generic
names are used as given in the Merck Index.
These compounds were compared at 1% con-
centration in water. In the few cases where
water solubility was too low, alcoholic solutions
were used. Grade 3—4 reactions (average of 5—10
subjects) were found for the active compounds,
1—2 for the slightly active compounds, and only
occasional weak reactions on one or two subjects
scattered among the inactive compounds. Pene-
tration, of course, is related to concentration and
some of the compounds hsted as "inactive" or
"slightly active" produced good sweat inhibition
at higher concentrations. However, in general the
1% concentration was deemed correct for screen-
ing purposes. Of course, ability to penetrate
the skin and intrinsic inhibitory activity are
Inactive
Dicyclomine IIC1
Hydroxyzine
Aturban
Darstine
Isopropamide
Tricyclamol
Meprobamate
Mothocarbamol
yalethamate Br
Piperoxan HCl
Diphemanil Methyl SO4
Styramate
Hexamethonium Br
Piperphenidol HC1
Atropine HBr
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both important factors. At this stage of the
study no effort was made to determine the in-
trinsic activity of the compounds against the
sweat glands. Thus, some of the poorly effective
compounds in this study would likely show good
activity if introduced by iontophoresis or intra-
dermal injection.
Two of the "active" compounds, scopolamine
methyl bromide and dibutoline sulfate, were
extensively studied by the axillary gravimetric
procedure. The first was found to inhibit sweat-
ing about 55% at 1% concentration; the latter,
60% at 5% concentration. Certainly these repre-
sent significant degrees of effectiveness.
It was decided to evaluate further as many
types of new compounds as possible of the
myriads of antieholinergies, spasmolyties, and the
like which have flooded the literature since the
end of World War II.
For discussion the compounds are divided
into esters; earbamates, thiocarbamates, and
urea derivatives; aminobutyramides, acid
amides; scopolamine derivatives; and miscel-
laneous compounds. Again, it is stressed that
all compounds were arbitrarily evaluated at
1% aqueous (or alcoholic) solution by the fore-
arm test. Many of those inactive under these
conditions would probably show activity at
higher concentrations or by iontophoresis or
by intradermal injection. In the ensuing tables
only a portion of the total number of com-
pounds is given. Most of the compounds with
activity are included with as many variations
in structures as possible.
Table II lists esters, other than atropine and
scopolamine. It can be seen that activity was
found for many structural types, and thus it can
be predicted that many structural types not in-
cluded in our studies if tested would also be
found to have some degree of activity. In
general the esters more often were found to
have good activity than the non-ester types
which are discussed later.
Most notable activity was found for com-
pound #39 in Table II. Axillary testing showed
45% sweat inhibition for 0.1% solutions. High
activity was also found for compounds #34 and
35. Other compounds with good activity were
#3, 4, 6, 7, 12, 17, 33, and 38. Of these 11 com-
pounds all except two contain one or more ele-
ments of the atropine structure; tropane (I),
1-methyl-4-hydroxypiperidine (II), or a sub-
stituted phenylacetie acid (III) which is ob-
viously related structurally to tropic acid (IV).
llO —CH,
(I)
HON—CH,
(II)
(OH)H 0
(III)
CH,0H
(IV)
While not all compounds with these structural
elements were active under the conditions tested,
very few compounds without these elements or
without at least a pyrrolidinol (V) or N-hy-
droxyethylpyrrolidine (VI) residue showed much
activity.
HO
-\
(V)
HO—CH2—CH2—NIj_(CH3)os
(VI)
These 11 most active compounds included 8
acid salts of tertiary amines (#3, 6, 7, 12, 17,
35, 38, and 39) and 3 quaternized amines
(*Z4, 33, and 34). Two of these 3 quaternized
compounds were about equally as active as
the tertiary amine acid salt counterparts (#34
& 35; 3 & 4). The other quaternized compound
(#33) did not have an analogous tertiary
amine counterpart for comparison. It is not
possible to generalize, however, that the tertiary
amine acid salt form will always be at least as
active as the quaternary salt counterparts. In
Table II, 2 of 10 such pairs (#15 & 16; 25 &
26) had quaternary forms which were more ac-
tive than the tertiary amine acid salts. Indeed
Table I showed that scopolamine methyl bro-
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mide was more effective than scopolamine hy-
drohromidc.
Although the information is meager, it would
appear that compounds quatcrnized with alkyl
halides of relatively short chain lengths are
more effective than those with longer chain
lengths.
Table III lists a number of carbamates, thio-
carbamates, and related urea structures which
showed a fair degree of short-lasting activity.
Both tertiary and quaternary compounds were
found to have activity. One of these (1) in
the axillary gravimetric procedure at 5% con-
centration produced about 60% sweat inhibition.
The relatively brief nature of the inhibition pro-
duced by these compounds makes them of less
interest than other compounds studied.
Table IV lists some substituted aminobutyra-
midcs, two of which possess a fairly good and
long-lasting degree of activity. Again both
tertiary and quaternary forms showed activity.
Translocation of a single methyl group in com-
pounds 1 and 2 drastically altered their activi-
ties.
Some related amidcs, none of which had much
activity, are given in Table V. Only atrolacta-
mide (3) showed much activity which at
best was short-lasting. This group is interesting,
however, in that a relatively simple structure,
devoid of the usual amino-alcoholic function,
possesses activity.
Among the compounds studied were a number
of scopolamine derivatives. Some of these were
found to possess good activity. Table VI lists
some of these. Activity in this series of com-
pounds was sufficiently high to require lower
concentrations (usually 0.1%) for separating
the active from the less active compounds.
Quaternizing scopolamine with methyl bromide
resulted in improved effectiveness. However, all
longer chain quaternary compounds were much
less effective.
Esterification of the OH group of the tropic
acid moiety of scopolamine in many cases re-
sulted in a profound increase in effectiveness,
although this was by no means universally the
case. The acetate ester was somewhat more
active than scopolamine. The quaternized form,
with methyl bromide, showed improved activity
as in the case of scopolamine. The N-oxide of
this acetate ester showed greatly diminished
activity while the N-oxide of scopolamine was as
active as scopolamine itself.
The carbanilate of scopolamine had poorer
activity than scopolamine as did the 3-cyclo-
propionate ester. On the other hand, the 2,2-
dimethylpropionate was more active than sco-
polamine. The preparation and study of other
scopolamine esters of even greater activity will
be discussed in Section II.
DIscussIoN
Ester structures of many types (Table II)
showed some degree of ability to inhibit sweat-
ing. The carbamates and other non-ester struc-
tures (Tables TII—V) also showed occasional ac-
TABLE III
Garbamates, thiocarbamates, and related ureas—1 .0%
R' 0
N—C—M—amine function/
B?'
S Source Se' Se" M Amine Function
Activity'
SHr 24Hr
1
2
3
4
5
6
7
Lilly
Merck
"
"
"
Lilly
Merck
C4H9
"
"
''
"
"
"
C4H9
"
"
''
"
"
"
0
NH
0
S
NH
0
0
—C2H4N(CH,)2 HC1
HC1
EtSO4
''
"
—C2114N(C2H5)2 HC1
—C2H4N(0H3)2 EtSO4
1
3
2
1
0
2
0
0
0
0
0
0
0
0
1 Forearm Test.
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TABLE IV
Substituted aminobutyramides—--i .0%
H\
N—C----—C—amine function
S Source R Amine Function
Activity'
5Hr 24Hr
1
2
3
4
5
6
7
8
Upjohn
Commercial
"
Upjohn
"
"
"
"
CH3
H
"
"
"
Gil3
H
"
—C,H4N(CH3), HC1
—CH2CH(CH,)N(CH,), HC1
—C2H4N(iso-C,H7)2 Mel
—C2H4NC(CH,)2CH,CH2CH2 3H,SO4
" MeBr
HC1
—C2H4NCH(CH,)CH,CH2CH,CH(CH3) HG!
MeBr
0
3
0
0
2
0
1
1
0
3
0
0
2
0
0
0
1 Forearm Test.
TABLE V
Acid Amides—1 .0%
QL<
S Source R' R" R" R" Activity'
5Hr 24Hr
1
2
3
4
5
6
7
8
9
10
11
Lilly
''
Pfeiffer
"
"
''
"
"
"
''
"
H
''
CH3
H
CII,
C,H,
CII,
"
"
''
H
OH
''
"
"
"
"
—OCOCH,
OH
"
"
—CH,OH
H
CIT3
H
C3H,
H
''
"
"
"
''
"
Cl3
''
"
C2H,
H
''
"
iso-C3H7
—C,H,OH
—C,H7
H
0
0
2
0
1
1
0
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
Forearm Test.
Dr. Carl C. Pfeiffer, Bureau of Research in Neurology and Psychiatry, New Jersey Neuro-Psychi-
atric Institute, Princeton, New Jersey.
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TABLE VI
,Scopolamine and atropine derivatives—O.1%
CH2OR'
__________
(J___O_<RH__CH3 >(o)
S Source R' R Activity1
SHr 24Hr
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Merck
Upjohn
"
"
"
P&G
Upjohn
"
"
"
"
"
"
P & G
Upjohn
"
"
"
"
H
"
"
"
"
"
"
"
—COd,
"
"
—CONHJ>—
—COC,H/"
—COC(CH,),
"
—COCH(C,H,),
"
HBr
MeBr
EtBr
—C,H4OH Br
—CH,CH=CH2 Br
—C4H,
—Berizyl Cl
N-oxide
HBr
MeBr
N-oxide
HBr
MeBr
HBr
MeBr
HBr
MeBr
HBr
MeBr
2
3
1
0
1
1
0
4
4+
4
0
0
0
1
3
4+
0
4+
1
1
2
1
0
0
0
0
2
4+
2
0
0
0
3
4
4+
0
4+
0
A tro pine Derivatives
20
21
Commercial H
"
H,SO
MeNO,
2
3
0
2
1 Forearm Test.
(VII)
Br
tivity. The incidence of activity is widespread lar structure to many of those included in Table
enough to predict that many other compounds II.
not tested will also show an effective inhibition o
of sweating. Long lasting and best activity, how-
ever, seemed to be associated with ester struc-
tures, in particular those which contained one
or more elements of the atropine or scopolamine
structure.
1
< " $I_O_\-=/ / /+ \
OH CII, CH,
The degree of effectiveness in axillary tests
ranged from 35 to 60% for 1% concentration of
several of the compounds which were most ac- The scopolamine esters of Table VI are clearly
tive on the forearm. These degrees of inhibition much more active than any of the other corn-
are similar to those found by Stoughton (4) pounds tested. The structures, vehicles, and
for compound AHR-483 (VII), an ester of simi- other factors which develop the optimal effee-
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tiveness for this series of compounds will he
discussed in Section II.
In no case in any of the work discussed above
was there any evidence of systemic side effects.
II Scopolamine and Atro pine Esters
The observed high degree of effectiveness in
inhibiting sweating after topical application of
the several scopolamine esters mentioned in the
previous section led to the synthesis of a con-
siderable number of other esters in order to
find the optimum structure. Included were esters
made from straight chain acids ranging from
C5 to C55, branched chain acids, cyclic aliphatic
acids, dicarboxylic acids, and aromatic acids.
With the finding of the most active structures,
TABLE VII
Antiperspirant activity of esters of scopolamine
hydrobromide—0.1 %
Esters
Activity
5 Hours 24 Hours 48 Hours
Unesterified 2 1 0
Straight Chain
Acetate 4 3 3
Propionatc 3 4 4
Butyrate 4+ 4+ 4+
Valerate 4+ 4+ 4+
Hexanoate 4 4 3
Hcptanoate 3 4 3
Octanoate 4 4 4
Nonanoate 4 4+ 4+
Decanoate 4 4+ 4+
Undecanoate 3 3 1
Laurate 1 2 1
Stearate 0.5 0.5 0
Oleate 0 0 0
Branched-Chain
Trimethylacetatc 4+ 4+ 4+
Isopropylacetate 4 4 4
2-Etbylbutyratc 4 4 4
2-Ethyl-3-Methylbutyrate 4 4 4
Isovaleratc 4+ 4+ 4+
4-Methylpentanotc 4 4 4
Cycloaliphatic
Cyclopcntylpropionatc 1 3 2
Cyclohexyipropionate 4 4+ 3
Aromatic
Benzoate 4+ 4+ 4+
2,4-Dichlorobcnzoate 4+ 4+ 4+
Naphthoatc 3 4+ 4
Forearm Test.
TABLE VIII
Antiperspirant activity of scopolamine
esters (0.05%)'
Ester Reduction inAxilisry Sweating
%
— 5
Acetate 10
Propionate 15
Butyrate 95
Trimethylacetate 95
2-Ethylbutyrate 90
Isovalerate 85
Stearate 10
Cyclohexylpropionate 80
Benzoatc 95
Naphthoate 85
1% Pluronic F-68 Matrix; pH 4.
2 Five hours following a single application.
further studies were done to determine the
effect of vehicle components, time of exposure,
degree of penetration, and intrinsic activity.
The scopolamine esters are not new com-
pounds, having been first synthesized and de-
scribed by Schmidt in 1892 (7). Although this
first reference made no mention of pharmaco-
logic activity, several other reports since then
have included some information on the pharma-
cologic action (6, 8).
From these reports there is no evidence to
show that the esters of scopolamine should show
any greater antiperspirant effectiveness than
scopolamine itself. The differences which ware
found, thus, appear to be related to improved
skin penetration rather than to greater intrinsic
anticholinergic activity.
RESULTS
Table VII shows the forearm antiperspirant
activity of 0.1% solutions of scopolamine esters
5, 24, and 48 hours following a single application
of 0.15 ml. Some of these esters showed activity
for more than 96 hours. Table VIII shows the
axillary antiperspirant effectiveness of 0.05%
solutions of these esters. In the axillary studies
1.0 ml of the solution which contained 1%
Pluronic F-68 (a non-ionic surfactant) at pH
4 was applied to the whole axillary surface.
The gravimetric sweat collections were made 5
hours after tipplication. The results in these
tables show that the C2 and C2 esters are clearly
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better than the parent compound itself. The
butyrate through decanoate esters, however,
show a much greater antiperspirant activity.
As the chain length is increased beyond C,,,
there is a decrease in effectiveness which is
probably related to decreased solubility and
poorer penetration. This is illustrated by the
stearoyl ester. The lauroyl and olcoyl esters also
showed the poor activity of the stcaroyl ester.
The cycloaliphatic esters and the aromatic
esters showed excellent activity also. All of
these esters may be applied in the form of the
free base or the acid salt with substantially
equal results. For practicality, however, the
acid salts arc preferred because of better water
solubility and much superior hydrolytic stabil-
ity at their lower solution pH's.
Table IX shows the forearm antiperspirant
activity of 0.1% solutions of a number of esters
of atropinc hydrobromidc. As with the scopola-
mine esters, testing was done at 5 and 24 hours.
It is readily seen that these esters do not possess
the high antiperspirant activity of the compara-
ble scopolamine esters. The deletion of the
cpoxide ring has a profound effect on the intrinsic
activity of the compounds or their penetration
into the skin. Injection studies done on one
pair of compounds showed that the intrinsic
sweat inhibitory activity of butyrylscopolamine
hydrobromide and butyrylatropine hydrobro-
mide were very similar; that is, the lowest
effective inhibitory concentration after injec-
tion was almost identical.' This is further proof
that the unique property of the scopolamine
ester is its ability to penetrate the skin.
Table X shows the forearm antiperspirant ac-
tivity of 0.1% solutions of esters of tertiary and
TABLE IX
Antiperspirant activity of esters of
atropine hydrobromide (0.1%)
Esters
Activity'
SHr 24Hr
—
Trimethylacetate
Butyrate
2-Ethylbutyrate
4-Methylpentanoate
Benzoate
2
0
0
0
0
0
0
0
0
0
0
0
asters
Activity'
5 Hr
HBc
24 Hr 45 Hr 5 Hr
3
CHIBr
24 Hr
4
48 Hr
3— 2 1 0
Acetate 4 4 4 3 2 0
Trimethylacetate....
2-Ethylbutyrate
2-Ethyl-3-methyl-
butyrate
Benzoate
4+
4+
4+
4+
4+
4+
4+
4+
4+
4+
4+
4+
0
1
0
1
0
0
0
2
0
0
0
0
TABLE XI
Influence of concentration of benzoylscopotamine
hydrobromide on axillary sweating
Concentration' Reduction in Axillary Sweating'
%
0.0025
0.0050
0.0250
0.050
%
35
60
85
95
'Matrix contained 1% Pluronic F-68; pH 4.
2 Three hours following a single application.
quaternary forms of scopolamine 5, 24, and 48
hours after a single application of 0.15 ml. It
is obvious that the tertiary ester is much more
active than its quaternized counterpart. This is
in contrast to the unesterified scopolamine, the
methyl bromide of which is more active than the
hydrobromide.
Since the 0.05% solutions of the scopolamine
esters produced such a high degree of effective-
ness, lower concentrations were evaluated. Table
XI shows results for benzoylscopolamine. Excel-
lent inhibition was found at 0.025% and signifi-
cant inhibition was observed down to 0.0025% or
even lower concentrations.
The influence of vehicle on the axillary anti-
perspirant activity of bcnzoylscopolamine is
shown in Figure 1. The antiperspirant activity
of this and other esters is greatly improved by
addition of a nonionic surfactant such as Flu-
ronic F-68 (a condensate of ethylene oxide with
a hydrophobic base formed by condensing
TABLE X
Antiperspirant activity of tertiary and quaternary
esters of scopolamine (0.1%)
1 Forearm Test.
Forearm Test.
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11% PLURONIC F—ES I
POLYETHYLENE GLICOLD I
11% DETYLTRIMETRYLAMMORIUM BROMIDE I
COLD CREAM I
WATER I
ETHANOL I
JI % Ro000ECYLBENDENE DIJLFONATEI
MINERAL OIL
SDLULAN
b 100do 40 do s
PER CENT INHIBITION OF AXILLARY SWEATING
FDa. 1. Influence of Matrix on Antiperspirant Ac-
tivity of 0.05% Benzoylscopolamine Hydrobro-
mide.
propyleneoxide with propylene glycol—molecu-
lar weight 8000). Cationic surfaetants such as
cetyltrimethylammonium bromide also appear
to improve penetration while anionic surfactants
such as dodecylbenzene sulfonate at concentra-
tions around 1% greatly reduced effectiveness. It
is expected that an ionic complex would form
between an anionic surfactant and the cationic
scopolamine ester (cationic at pH's below its
pKa). The deleterious effect of the dodecylben-
zene sulfonate is lost when the concentration
is reduced to 0.1% or lower; thus, a considerable
excess is required for the inactivation observed
above.
A mixture of carbowaxes such as the 1500
and 4000 (Carbowax—solid polyethylene gly-
cols; Carbowax 1500, average molecular weight
500 to 600; Carbowax 4000, average molecular
weight 3000 to 3700) in a ratio of 5:3 serves as
an acceptable vehicle for the scopolamine esters
as did a cold cream base. Mineral oil, Solulan
(a waxy lanolin derivative), and a waxy fat
such as stearoyl diacetin greatly decreased the
efficacy of these esters when they were used as
the vehicle.
Figure 2 shows the effect of axillary contact
time on the antiperspirant effectiveness of
0.025% bcnzoylscopolamine hydrobromide from
a 1% Pluronic F-68 matrix. The procedure fol-
lowed in this study was to apply 1.0 ml of the
test solution to one axilla (the other axilla
being untreated). After a given contact time
(which is the time between application and
wash-off) both axillac were thoroughly washed
with soap and water and then dried. The sub-
ject was then placed in a 100 F room at 40%
relative humidity for a 30-minute period prior
to the taking of axillary gravimetric sweat col-
lections.
When the benzoyl ester was allowed to remain
in contact with the axilla for 60 minutes prior
to wash-off, maximum antiperspirant effective-
ness was achieved between 4 to 6 hours. Good
activity continues beyond 7 hours. A 15-minute
contact period resulted in the same maximum
degree of sweat inhibition as was observed for
the 60-minute contact period. However, the
reduction in sweating shown over the first 3
hours was approximately 30% less. The sweat
inhibition pattern observed following a 5-minute
axillary contact period paralleled that of 15 min-
utes during the first few hours after application.
Maximum inhibition was still achieved between
S and 6 hours but was less than that observed
following a 15-minute axillary contact period.
The lasting effects following a 5-minute contact
period begin to fall off significantly after 7
hours.
This sequence of events indicates a very rapid
penetration into the stratum corneum. However,
an hour or so is required for the material to
traverse the barrier layer, the rest of the epider-
mis, and the dermis to the sweat gland. The
build-up in effectiveness from 1 hour through
5 to 6 hours reflects continued absorption, and
saturation of the epidermis and dermis, at a
rate more rapid than inactivation or hydrolysis
occurs in the tissues. The slow drop-off in effec-
tiveness after 6 hours indicates that absorption
is essentially complete, and destruction of the
compound slowly depletes it from the site of
action at the sweat gland. When the anticholiner-
gic is not washed off or when higher concentra-
tions are used, the skin acts as a reservoir which
az
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j40 T 4 —e 60 MINUTES22 30 s——A IS MINUTES
• •U 0.—D 5 MINUTESth2O IIO
',
At /0
I 2 3 4 5 6 7 S
HOURS FOLLOWING APPLICATION
Fio. 2. Effect of Axillary Contact Time of 0.025%
Benzoylscopolamine Hydrobromide on Antiper-
spirant Effectiveness.
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continually feeds the compound into the sweat
gland area for longer time intervals.
DISCUSSION
Some of the scopolamine esters have a great
ability to penetrate the intact skin. The benzoyl
ester for example produces equivalent inhibition
of sweating on the forearm at from 1/100 to
1/1000 the concentration of scopolamine. Com-
parison of the effectiveness of intracutaneously
injected and topically applied butyrylseopola-
mine showed the minimal inhibitory concentra-
tion of the 0.05 ml injection solution to be about
a 10° dilution; that is, about 0.0005 pg. An
area about 3—4 mm in diameter was inhibited by
this amount of the scopolamine ester. Topically,
0.1 ml of a 0.01% solution (that is, about 10
pg) of the same ester will produce inhibition of
an area of about 4.5 em2. Thus, by injection
0.0005 pg inhibited an area of about 12 mm2,
while topically 10 pg inhibited an area of about
12,000 mm2. Calculations of this sort, while
admittedly rough, do indicate that a relatively
large portion of the applied scopolamine ester
has the ability to penetrate the intact skin.
The best estimate is that perhaps 5—10% of
the material penetrates. Thus, it is not sur-
prising that some of these compounds do ex-
hibit such a high level of effectiveness.
Such high penetration through normal skin
lessens the possibility of untoward side effects
by absorption through injured or diseased skin
because the concentration that can be used is
so low. Safety, of course, is a key factor in de-
termining whether scopolamine esters can be
used. The following section deals with this
aspect of the problem.
III Evaluation of the Safety of Benzoyl-
scopolamine Hydrobromide
Studies have been carried out to evaluate the
safety of benzoylscopolamine hydrobromide from
the standpoints of systemic effects resulting
from percutaneous absorption, irritation, and
sensitization of the skin. This work was done
under careful medical supervision with full cog-
nizance of the systemic responses to scopolamine
which might be observed.2
work was done under the supervision of
Dr. Albert M. Khgman, Department of Dermatol-
ogy, University of Pennsylvania School of Medi-
cine.
RESULTS AND DISCUSSION
To establish a baseline for interpreting the
effects of topical application, benzoylscopola-
mine hydrobromide was administered to groups
of 20 adult male subjects, orally or subcutane-
ously. As shown in Table XII, a dose of 0.06 mg
of the compound elicited no evidence of systemic
response by either route of administration.
From 10% to 20% of the subjects experienced
dryness of the mouth and blurring of vision at
a dose of 0.125 mg; the incidence increased
to 55—70% with a dose of 0.25 mg. There were,
as indicated, some reports of dizziness at the
higher levels. Subcutaneous administration ap-
peared to cause somewhat greater reactions
than did ingestion, although essentially complete
absorption from the G.I. tract must have oc-
curred.
For comparison, groups of 10 or 20 adult
male subjects received twice-daily applications
of solutions of benzoylscopolamine hydrobro-
mide, at a level of 0.2 ml of solution per axilla
per application. Table XIII shows that minor
symptoms were seen in 15% of the subjects
after 4 days' treatment with the 0.25% solution
(2 mg/day), in 70% after 3 days' treatment with
the 0.5% solution (4 mg/day), and in 80%
TABLE XII
Systemic response following oral and parenteral
administration of benzoylscopolamine HBr to
normal human volunteers
Dry mouth,
blurred vision
Dry mouth,
blurred vision
(four reported
dizziness)
Dry mouth,,
blurred vision
(one reported
dizziness)
More severe, dry
mouth, blurred
vision (five re-
ported dizzi-
ness)
Degree of ReactionRoute
Oral
Subcutaneous
Dose-Mg.
0.06
0.125
0.25
0.06
0.125
0.25
Subjects
Respond-
ing
0/20
2/20
11/20
0/20
4/20
14/20
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TABLE XIII
Systemic response following application of
benzoylscopolamine HBr to axillae of
normal human volunteers'
Benzoylscopol-
amine HBr
Applied
Cnnc. % Mg/Day
Subjects
Responding
Mn. Days
Natuce nt Response
0.1
0.25
0.5
1.0
5.0
0.8
2.0
4.0
8.0
40.0
0/20
3/20
14/20
8/10
10/10
7 i
4
3
1
1
—
Dry mouth
Dry mouth
Dry mouth, blurred
vis'on
Blurred vision, dizzi-
ness, dilated pupils
(four emotionally
disturbed)
'0.2 ml/axilla/twiee daily.
alter the first day's exposure to the 1% solution
(8 mg/day). All ten subjects showed marked
reactions after one day to the 5% solution (40
mg/day). Comparison with the results presented
in the previous table suggests that the dose
required to produce a given level of systemic
response by topical application to the axillae is
about 20 times as great as the oral or subcu-
taneous dose needed to produce a similar ef-
fect. (This constitutes further evidence that
5—10% of the topically applied dose penetrates
the skin.)
A further investigation was designed to de-
termine the possibility of systemic effects re-
sulting from over-exposure to a 0.025% solution
of benzoylscopolamine hydrobromide, a concen-
tration that is very effective in the control of
sweating. Forty adult subjects (20 male and 20
female) received daily applications of 0.25 ml
of the solution to each axilla and, initially, 0.5
ml to the upper arm. Every day the application
over the body surface was increased by 0.5 ml
until the dose reached 22 ml. No effect was seen
even when the total body surface was covered
each day for several days. (An 8-ml dose was
sufficient to cover the entire cutaneous surface.)
Some individuals showed the initial signs of
mouth dryness at a dose of 12 ml (body surface
covered 1½ times), and the treatment of some
subjects was discontinued at the 15-ml level
because of marked discomfort. About half the
subjects showed symptoms at 16 ml, and all
were affected at 20—22 ml. Blurring of vision
became a more frequent complaint at higher
dosages, and a few individuals reported gastro-
intestinal distress and some difficulty in urina-
tion. All adverse effects disappeared within 24
to 36 hours after cessation of treatment.
No evidence of skin irritation was seen in any
of this work or in any of the screening studies
reported in Sections I and II.
Fifty adult males served as subjects in a test
for contact sensitization. One-inch squares of
cotton flannel were saturated with a 0.5% solu-
tion of benzoylscopolamine hydrobromide, and
these were placed on the intact skin of the
forearm, under an occlusive dressing, for 3
days; the procedure was repeated for 2 addi-
tional 3-day periods. After a 2-week rest period,
a 48-hour challenge patch was applied in the
same way. In no instance was there any evidence
of irritation or sensitization.
Axillary biopsy specimens taken from 5 male
human volunteers following twice-daily applica-
tion of 0.5 ml of a 0.025% benzoylscopolamine
hydrobromide solution for 8 weeks did not
show any demonstrable histological changes
when compared to the control specimens.
It is concluded that a sufficient margin of
safety exists for the use of certain scopolamine
esters as effective topical antiperspirants. Highly
effective concentrations (0.025%) would have to
cover the whole body surface more than once
before minimal systemic effects would be noted.
Complete absorption of the material applied to
an area the size of both axillae (estimated 0.5
ml) would not be expected to produce any sys-
temic-symptoms.
5UMMARY
1. A variety of antieholinergic structures have
been found to inhibit sweating after topical
application. Among the various structures in-
vestigated, esters were found to have the best
activity of a long lasting nature.
2. The most effective compounds were most
often esters which contained one or more ele-
ments of the atropine or scopolamine structure.
3. Esters of scopolamine hydrobromide were
found to be much more effective than any other
type of structures studied.
4. Most effective esters include straight,
branched, and cyclic aliphatic esters, and aro-
matic esters, although most types studied were
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more efficient than scopolamine in the unesteri-
fled form.
5. The high effectiveness of the scopolamine
esters is related to their very high skin penetra-
bility (perhaps 5—10% of the amount applied)
not to improved antieholinergie activity.
6. Evaluation of safety of the benzoyl ester
of scopolamine showed that 0.025% solution can
he used repeatedly on a limited area of the
body without any incidence of systemic effects.
The whole body surface must be covered more
than once to produce even the most minimal
systemic effect.
7. Skin irritation or sensitization did not occur
in studies run with benzoylseopolamine.
S. These compounds constitute the first highly
effective topical sweat inhibition agents of the
antieholinergie type.
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